Research Topics
| Keith C FerdinandSummaryAffiliation: Heartbeats Life Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Community-based approaches to prevention and management of hypertension and cardiovascular diseaseKeith C Ferdinand
American Society of Hypertension Community Outreach Program, Tulane Heart and Vascular Institute, Tulane University School of Medicine, 1430 Tulane Avenue, SL 48, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 14:336-43. 2012..Contemporary major federal programs, such as the Million Hearts Initiative, are ongoing. Overall, the evidence-based Logic Model should enhance planning, implementation, and dissemination...- Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertensionKeith C Ferdinand
Division of Cardiology, Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70112, USA
J Am Soc Hypertens 6:219-27. 2012..However, because our subgroups were not mutually exclusive, the generalization of our findings to the population seen in clinical practice is limited... - One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose responseKeith C Ferdinand
Association of Black Cardiologists and Atlanta Clinical Research Center, Tucker, GA 30084, USA
Am J Cardiovasc Drugs 12:117-25. 2012.... - Hypertension in the US Black population: risk factors, complications, and potential impact of central aortic pressure on effective treatmentKeith C Ferdinand
Division of Cardiology, Tulane University School of Medicine and Association of Black Cardiologists, Inc, 1430 Tulane Ave, SL 48, New Orleans, LA 70112, USA
Cardiovasc Drugs Ther 26:157-65. 2012..The purpose of this paper is to review these factors and discuss how they present unique opportunities for improving the management of hypertension in this difficult-to-treat population... 
Coronary artery disease in minority racial and ethnic groups in the United StatesKeith C Ferdinand
Heartbeats Life Center and Department of Clinical Pharmacology, Xavier University College of Pharmacy, New Orleans, Louisiana, USA
Am J Cardiol 97:12A-19A. 2006..There remain significant challenges to understanding racial/ethnic differences in cardiovascular risk factors and to including minority groups in clinical trials of therapeutic interventions, thereby ensuring optimal treatment for all...- Trends in hypertension treatment in diabetesKeith C Ferdinand
Association of Black Cardiologists, 5355 Hunter Road, Atlanta, GA 30349, USA
Curr Hypertens Rep 11:437-43. 2009..Clinical evidence may soon confirm or refute the outcomes benefit of blood pressure targets of 120/80 mm Hg or lower... - Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitusKeith C Ferdinand
Association of Black Cardiologists, Atlanta, GA 30349, USA
J Clin Hypertens (Greenwich) 11:585-93. 2009..9 mg vs maximum of 80 mg). Reluctance to intensify therapy to attain accepted targets in high-risk individuals suggests a degree of clinical inertia not explained by objective evidence of dose-dependent intolerance... - African American heart failure trial: role of endothelial dysfunction and heart failure in African AmericansKeith C Ferdinand
Division of Cardiology and the Clinical Research Center, Morehouse School of Medicine, Atlanta, Georgia 30310, USA
Am J Cardiol 99:3D-6D. 2007..When added to standard therapy, isosorbide dinitrate and hydralazine provide an evidence-based approach to diminishing morbidity and mortality in this high-risk population... - The management of hypertension with angiotensin receptor blockers in special populationsKeith C Ferdinand
Division of Cardiology Emory University School of Medicine, Atlanta, Georgia 30349, USA
Clin Cornerstone 9:S5-17. 2009..Although at least 1 major study has confirmed the benefit of ARBs in Asian patients with diabetic nephropathy, overall, treating patients based on race and ethnicity remains fraught with difficulty... - Achieving treatment goals in low-risk, asymptomatic patientsKeith C Ferdinand
Division of Cardiology, Emory University
J Am Osteopath Assoc 110:S7-13. 2010..As the present case-based activity demonstrates, determining appropriate diagnostic and management strategies according to CHD risk is a process that challenges physicians to consider myriad individual patient variables... - Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertensionKeith C Ferdinand
Emory University, Atlanta, GA 30349, USA
J Am Soc Hypertens 5:102-13. 2011..2% and 40.2%, respectively. Combination aliskiren/amlodipine therapy was effective in treating these high-risk patients but inclusion of HCTZ provided greater antihypertensive efficacy. Both treatments were similarly well tolerated... - Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trialKeith C Ferdinand
Cardiology Division, Emory University, Atlanta, GA 30349, USA
J Clin Hypertens (Greenwich) 13:366-75. 2011..Central pressure is considered an important risk factor in African Americans, and these findings may suggest a new treatment option for these patients... - Management of hypertension and dyslipidemiaKeith C Ferdinand
Association of Black Cardiologists, Inc, 5355 Hunter Road, Atlanta, GA 30349, USA
Curr Hypertens Rep 8:489-96. 2006..Patient adherence may affect achievement of recommended goals of therapy for dyslipidemia and hypertension. Effective education and communication may improve overall achievement of treatment goals... - Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndromeKeith C Ferdinand
Heartbeats Life Center, New Orleans, LA, USA
J Cardiometab Syndr 1:133-40. 2006.... - Are cardiovascular benefits in statin lipid effects dependent on baseline lipid levels?Keith C Ferdinand
Division of Cardiology, Emory University, 5355 Hunter Rd, Atlanta, GA 30349, USA
Curr Atheroscler Rep 13:64-72. 2011..Preconceived notions on statin benefit or harm do not enhance patient care and clinicians should individualize long-term statin therapy... - Race-based therapy for hypertension: possible benefits and potential pitfallsKeith C Ferdinand
Division of Cardiology, Emory University, Atlanta, GA, USA
Expert Rev Cardiovasc Ther 6:1357-66. 2008..Current guidelines recommend thiazide diuretics and/or long-acting calcium channel blockers as initial treatment for Blacks, although medications for compelling indications agents should be prescribed, regardless of race/ethnicity... - Ethnic, gender, and age-related differences in the treatment of dyslipidemiaKeith C Ferdinand
Emory University Chief Scientific Officer of Association of Black Cardiologists, 5355 Hunter Rd, Atlanta, GA 30349, USA
Am J Manag Care 12:S400-4. 2006..This article will explore the evidence for instituting statin therapy as part of a risk reducing strategy in older individuals, women, and ethnic minorities... - Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA studyBobby V Khan
Atlanta Vascular Research Foundation, Atlanta, GA 30084, USA
J Cardiovasc Pharmacol Ther 17:291-7. 2012..We investigated the effects of nebivolol with the diuretic hydrochlorothiazide (HCTZ) in hypertensive African Americans with echocardiographic evidence of diastolic dysfunction... - The management of hypertension in African AmericansKeith C Ferdinand
Association of Black Cardiologists, Critical Pathways in Cardiology, Boston, MA 02115, USA
Crit Pathw Cardiol 6:67-71. 2007..Of note, African American patients with systolic BP >15 mm Hg or a diastolic BP >10 mm Hg above goal should be treated with first-line combination therapy... - Hypertension-related morbidity and mortality in African Americans--why we need to do betterKeith C Ferdinand
Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, LA, USA
J Clin Hypertens (Greenwich) 8:21-30. 2006..These comorbidities are more common in African Americans and indicate the potential need for initial therapy with more than one agent or a combination of agents in one pill... - Recommendations for the management of special populations: racial and ethnic populationsKeith C Ferdinand
Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, Louisiana 70117, USA
Am J Hypertens 16:50S-54S. 2003..Although certain combinations have been shown to be effective in non-African American patients, the choice of drugs for combination therapy in African American patients may be different... - Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trialKeith C Ferdinand
Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, Louisiana, USA
Am J Cardiol 97:229-35. 2006..In conclusion, rosuvastatin 10 and 20 mg improved the overall lipid profile of hypercholesterolemic African-Americans better than did milligram-equivalent doses of atorvastatin... - Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial functionNadya Merchant
Department of Cardiology, Emory University, 69 Jesse Hill Drive SE, Atlanta, GA30303, USA
J Clin Hypertens (Greenwich) 11:720-5. 2009..005). Monotherapy with nebivolol in obese, hypertensive African Americans results in significant systolic and diastolic BP reduction by mechanisms that include improved vascular function and compliance... - Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con positionKeith C Ferdinand
Heartbeats Life Center, Xavier University of Louisiana, College of Pharmacy, 1201 Poland Avenue, New Orleans, LA 70117, USA
Curr Hypertens Rep 4:311-8. 2002..The use of evidence-based therapies should be equally applied to African-Americans as well as to other ethnic groups while awaiting further studies... 
Managing cardiovascular risk in minority patientsKeith C Ferdinand
Heartbeats Life Center, New Orleans, LA 70117, USA
J Natl Med Assoc 97:459-66. 2005..Large, ongoing epidemiologic and clinical trials will add to our knowledge of cardiovascular risk in these minority populations and contribute to recommendations to improve risk management...- The metabolic syndrome: recognition and managementW Dallas Hall
Emory University School of Medicine, Atlanta, GA, USA
Dis Manag 9:16-33. 2006..Pharmacotherapy is typically needed for control of high blood pressure, hypercoagulability, and increased levels of blood glucose and triglycerides... - Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?Keith C Ferdinand
Heartbeats Life Center, New Orleans, LA, USA
J Cardiometab Syndr 1:146-8. 2006.... - Rosuvastatin: a risk-benefit assessment for intensive lipid loweringKeith C Ferdinand
College of Pharmacy, Xavier University, New Orleans, LA 70117, USA
Expert Opin Pharmacother 6:1897-910. 2005..Therefore, rosuvastatin offers an effective alternative in the clinical management of hyperlipidaemia, while awaiting the results of ongoing cardiovascular risk reduction trials... - Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapyElizabeth O Ofili
Clinical Research Center, Morehouse School of Medicine, Atlanta, GA 30310, USA
J Natl Med Assoc 98:618-26. 2006..In conclusion, irbesartan/HCTZ treatment provided SBP/DBP goal attainment in approximately two-thirds of Caucasian, African-American and Hispanic/Latino patients with SBP uncontrolled on antihypertensive monotherapy... - The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY studySyed T Rahman
Emory University School of Medicine, Division of Cardiology, Atlanta, GA, USA
J Cardiovasc Pharmacol Ther 17:139-45. 2012.... - Coronary heart disease and lipid-modifying treatment in African American patientsKeith C Ferdinand
Heartbeats Life Center, New Orleans, LA 70117, USA
Am Heart J 147:774-82. 2004..Educational outreach programs can provide a key role in raising community awareness of CHD risk factors and potential treatment options... - Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?Keith C Ferdinand
Cardiology Division, Emory University, USA
J Law Med Ethics 36:458-63. 2008..Future research may unmask the reason for cardiovascular differences in therapy... - Cardiovascular disease in blacks: can we stop the clock?Keith C Ferdinand
Emory University and the Association of Black Cardiologists, Atlanta, GA 30349, USA
J Clin Hypertens (Greenwich) 10:382-9. 2008..However, renin-angiotensin system modulators may also be beneficial, especially with a diuretic, considering the high prevalence in this group of patients of compelling indications for use of such agents... - The cardiometabolic syndrome and cardiovascular disease in racial and ethnic minorities: new areas of research and interventionKeith C Ferdinand
Association of Black Cardiologists, Atlanta, GA
J Cardiometab Syndr 2:235-7. 2007 - Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular diseaseKeith C Ferdinand
Heartbeats Life Center, New Orleans, LA 70117, USA
Curr Med Res Opin 21:1091-7. 2005..This subset of at-risk patients is better served by this approach than by treatment solely based on degree of dyslipidemia... - Hypertension in minority populationsKeith C Ferdinand
Association of Black Cardiologists, Inc, Atlanta, GA 30349, USA
J Clin Hypertens (Greenwich) 8:365-8. 2006..7% to 0.8%. Asians and Pacific Islanders as a category will become a larger proportion, from 3.9% to 6.2%. The largest increase in proportion will be seen in those identified as Hispanic (of any race), from 11.8% in 2002 to 18.2% in 2025... - Public health and Hurricane Katrina: lessons learned and what we can do nowKeith C Ferdinand
Association of Black Cardiologists Hurricane Katrinia Relief, Atlanta, GA, USA
J Natl Med Assoc 98:271-4. 2006..The hurricane destroyed hiss cardiovascular center and severely damaged his home. In Atlanta, he is director of the Association of Black Cardiologists Hurricane Katrina Relief... - The importance of aggressive lipid management in patients at risk: evidence from recent clinical trialsKeith C Ferdinand
Heartbeats Life Center and Xavier University College of Pharmacy, New Orleans, Louisiana 70017, USA
Clin Cardiol 27:III12-5. 2004..Taken together, the results of these landmark trials not only support aggressive lipid lowering in patients at risk for CHD, but also suggest that greater LDL-C reductions may improve outcomes across a wide range of patients... - Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safetyKeith C Ferdinand
Xavier University, College of Clinical Pharmacology, New Orleans, LA, USA
Expert Rev Cardiovasc Ther 3:993-1001. 2005..Further clinical trials utilizing isosorbide dinitrate will hopefully determine the benefit of this combination in a larger population, including caucasians and other racial/ethnic groups... - Hypertension and the cardiometabolic syndrome--is it the blood pressure lowering or the blood pressure medication that is important?Keith C Ferdinand
From the Heartbeats Life Center, Xavier University College of Pharmacy, New Orleans, LA, USA
J Cardiometab Syndr 1:72-3. 2006..This case illustrates some of the factors clinicians have utilized in approaching patients with this common but challenging clinical situation... - From protocol to practice: translating the clinical data into clinical practiceKeith C Ferdinand
Heartbeats Life Center, 1201 Poland Ave, New Orleans, LA 70117, USA
Postgrad Med 112:18-22. 2002..Clearly, future studies must include more representative samples from these populations. Meanwhile, the Adult Treatment Panel III guidelines should be applied across the board... - New evidence confirms risks associated with prehypertension and benefits of therapeutic lifestyle changes in managementKeith C Ferdinand
Association of Black Cardiologists, Atlanta, GA 30349, USA
J Cardiometab Syndr 2:302-4. 2007..Based on her BP and concurrent cardiometabolic syndrome, what do you tell her about the risks associated with her BP, and how do you approach her management?.. - The epidemic of diabetes mellitus and the metabolic syndrome in African AmericansKeith C Ferdinand
Xavier University College of Pharmacy, Heartbeats Life Center, New Orleans, Louisiana, USA
Rev Cardiovasc Med 5:S28-33. 2004..Appropriate lifestyle modification programs, glucose control, and cardiovascular risk reduction therapy will reduce the excessive morbidity and mortality in this population... - Cardiovascular health in patients with serious mental illnesses: we need to do moreKeith C Ferdinand
Association of Black Cardiologists, Atlanta, GA, USA
J Clin Hypertens (Greenwich) 9:714-5. 2007 - Introduction: management of hypertension and cardiovascular risk factors in African AmericansKeith C Ferdinand
Heartbeats Life Center, New Orleans, LA 70117, USA
J Clin Hypertens (Greenwich) 5:3-4. 2003 - The Hurricane Katrina disaster: focus on the hypertensive patientKeith C Ferdinand
Heartbeats Life Center, New Orleans, LA, USA
J Clin Hypertens (Greenwich) 7:679-80. 2005 - Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in BlacksJanice G Douglas
Case Western Reserve University, Department of Medicine, Room W-165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
Arch Intern Med 163:525-41. 2003 - Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcomeJames R Sowers
Departments of Medicine, Biochemistry, and Cell Biology, State University of New York Health Science Center, Brooklyn College of Medicine, Brooklyn, NY 11203, USA
Postgrad Med 112:24-6, 29-30, 33-4 passim. 2002..In this article, Drs Sowers, Ferdinand, Bakris, and Douglas examine the biologic, social, and genetic factors that contribute to these health disparities, the risk for which appears in early childhood... - Retrospective analysis: consensus statement of the hypertension in African Americans working group of the International Society on Hypertension in Blacks (ISHIB)Keith C Ferdinand
Ethn Dis 15:3-5. 2005 - A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensivesMatthew R Weir
Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Hypertension 46:508-13. 2005..5 mg) is as effective as high-dose amlodipine (10 mg) in reducing blood pressure in blacks with stage 1 and stage 2 hypertension, and valsartan/hydrochlorothiazide is better tolerated... - The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trialJoel M Neutel
Orange County Research Center, Tustin, CA 92780, USA
J Clin Hypertens (Greenwich) 7:578-86. 2005..Treatments were well tolerated. This irbesartan/HCTZ treatment regimen achieved SBP goals in more than 75% of patients uncontrolled on monotherapy... - Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goalsGeorge L Bakris
Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
Postgrad Med 112:73-4, 77-80, 83-4. 2002..This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies... - The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?Keith C Ferdinand
J Clin Hypertens (Greenwich) 8:156-8. 2006 - Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetesJames R Sowers
University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
J Clin Hypertens (Greenwich) 8:470-80. 2006..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy... - New antihypertensive agents: will they work in blacks?Keith C Ferdinand
J Clin Hypertens (Greenwich) 9:165-7. 2007 - Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure TrialJalal K Ghali
University Health Center, Wayne State University, Detroit, MI 48201, USA
Am J Cardiovasc Drugs 7:373-80. 2007.... - Cardiovascular disease and African Americans: why determination of race is inadequate for research and practiceKeith C Ferdinand
J Natl Med Assoc 99:686-9. 2007 - The management of hypertension in the African American patientJackson T Wright
Medicine, Case Western Reserve University, Cleveland, OH, USA
J Clin Hypertens (Greenwich) 9:468-75. 2007..The authors maintained full control of the discussion and the resulting content of this article; Novartis had no input in the choice of topic, speakers, or content... - Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trialJohn M Flack
Department of Medicine, Wayne State University, Detroit, MI 48201, USA
Mayo Clin Proc 83:35-45. 2008..To investigate the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African Americans... - Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapyWilliam C Cushman
University of Tennessee College of Medicine and Veterans Affairs Medical Center, Memphis, TN, USA
Am J Geriatr Cardiol 17:27-36. 2008..Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy... - Barbershops as hypertension detection, referral, and follow-up centers for black menPaul L Hess
Division of Hypertension, Donald W Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8586, USA
Hypertension 49:1040-6. 2007..01). Taken together, these data suggest that black-owned barbershops can be transformed into effective HTN detection, referral, and follow-up centers. Further research is warranted... - Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attainedJanice G Douglas
Division of Hypertension, Department of Medicine, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Room W165, 10900 Euclid Ave, Cleveland, OH 44106 4982, USA
Postgrad Med 112:51-2, 55, 59-62 passim. 2002..When extensive efforts to achieve blood pressure control prove unattainable in the primary care setting, consultation with a hypertension specialist should be considered... - Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trialPeter H Jones
Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Ther 26:1388-99. 2004.... - The Metabolic Syndrome in African Americans: a reviewW Dallas Hall
African American Lipid and Cardiovascular Council, USA
Ethn Dis 13:414-28. 2003..This comprehensive review is provided as part of the educational activities of the African-American Lipid and Cardiovascular Council (AALCC)... - For the patient. What is the Metabolic Syndrome and why is it important?W Dallas Hall
Ethn Dis 13:546. 2003 - Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?George L Bakris
University of Chicago, IL, USA
Prev Cardiol 11:42-9. 2008..The authors maintained full control of the discussion and the resulting content of this article... - Roundtable discussion: hypertension, renal disease, and diabetesMarvin Moser
J Clin Hypertens (Greenwich) 4:113-9. 2002..Following a symposium on Hypertension in Atlanta, Georgia on April 25, 2001, which was sponsored by the National Heart, Lung, and Blood Institute, a panel was convened to discuss the problems of renal disease and hypertension... - Noninvasive diagnosis of subclinical atherosclerosis in cardiometabolic syndrome: a call to actionCarol Kotliar
Cardiology Department, Hospital Universitario Austral, Buenos Aires, Argentina
J Cardiometab Syndr 3:60-2. 2008